Neuropathology of nondemented aging: Presumptive evidence for preclinical Alzheimer disease

Department of Anatomy and Neurobiology, Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.
Neurobiology of aging (Impact Factor: 4.85). 05/2009; 30(7):1026-36. DOI: 10.1016/j.neurobiolaging.2009.04.002
Source: PubMed

ABSTRACT To determine the frequency and possible cognitive effect of histological Alzheimer's disease (AD) in autopsied older nondemented individuals.
Senile plaques (SPs) and neurofibrillary tangles (NFTs) were assessed quantitatively in 97 cases from 7 Alzheimer's Disease Centers (ADCs). Neuropathological diagnoses of AD (npAD) were also made with four sets of criteria. Adjusted linear mixed models tested differences between participants with and without npAD on the quantitative neuropathology measures and psychometric test scores prior to death. Spearman rank-order correlations between AD lesions and psychometric scores at last assessment were calculated for cases with pathology in particular regions.
Washington University Alzheimer's Disease Research Center.
Ninety-seven nondemented participants who were age 60 years or older at death (mean=84 years).
About 40% of nondemented individuals met at least some level of criteria for npAD; when strict criteria were used, about 20% of cases had npAD. Substantial overlap of Braak neurofibrillary stages occurred between npAD and no-npAD cases. Although there was no measurable cognitive impairment prior to death for either the no-npAD or npAD groups, cognitive function in nondemented aging appears to be degraded by the presence of NFTs and SPs.
Neuropathological processes related to AD in persons without dementia appear to be associated with subtle cognitive dysfunction and may represent a preclinical stage of the illness. By age 80-85 years, many nondemented older adults have substantial AD pathology.

Download full-text


Available from: Walter A Kukull, Aug 15, 2015
  • Source
    • "One the other hand, critics have found to focus on limitations in the methodology of clinical trials and on bias in the way the data are introduced, especially in trials sponsored by drug companies, and have concluded that efficay of drugs are inflated (Casey et al., 2010). One of the most important problems leading to difficulty in disease management is AD pathology existed in brain cells many years before the appearance of clinical symptoms (Price et al., 2009). AD is distinguished mainly by neuronal loss. "
    Saudi Pharmaceutical Journal 01/2015; 35. DOI:10.1016/j.jsps.2015.01.017 · 1.00 Impact Factor
  • Source
    • "By itself the ε4 allele does not doom one to certain death by AD or vascular disease, nor does the accumulation of plaques and tangles lead to dementia in all cases. Post mortem analyses of brains have uncovered many cases in which AD type plaques and tangles are present without the expected deficits in cognitive function (Davis et al., 1999; Price et al., 2009; Balasubramanian et al., 2012). Conversely, in studies of very old adults—individuals 80 to 100+ years old—up to 50% of dementias previously diagnosed as AD were later determined to be of unknown etiology (i.e., postmortem analysis failed to identify brain pathology typical of AD or other dementias; Crystal et al., 2000; Imhof et al., 2007; Middleton et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: As of 2010, the worldwide economic impact of dementia was estimated at $604 billion USD; and without discovery of a cure or effective interventions to delay disease progression, dementia’s annual global economic impact is expected to surpass $1 trillion USD as early as 2030. Alzheimer’s disease (AD) is the leading cause of dementia accounting for over 75% of all cases. Toxic accumulation of amyloid beta (Aβ), either by overproduction or some clearance failure, is thought to be an underlying mechanism of the neuronal cell death characteristic of AD—though this amyloid hypothesis has been increasingly challenged in recent years. A compelling alternative hypothesis points to chronic neuroinflammation as a common root in late-life degenerative diseases including AD. Apolipoprotein-E (APOE) genotype is the strongest genetic risk factor for AD: APOE-ε4 is proinflammatory and individuals with this genotype accumulate more Aβ, are at high risk of developing AD, and almost half of all AD patients have at least one ε4 allele. Recent studies suggest a bidirectional relationship exists between sleep and AD pathology. Sleep may play an important role in Aβ clearance, and getting good quality sleep vs. poor quality sleep might reduce the AD risk associated with neuroinflammation and the ε4 allele. Taken together, these findings are particularly important given the sleep disruptions commonly associated with AD and the increased burden disrupted sleep poses for AD caregivers. The current review aims to: (1) identify individuals at high risk for dementia who may benefit most from sleep interventions; (2) explore the role poor sleep quality plays in exacerbating AD type dementia; (3) examine the science of sleep interventions to date; and (4) provide a road map in pursuit of comprehensive sleep interventions, specifically targeted to promote cognitive function and delay progression of dementia.
    Frontiers in Aging Neuroscience 12/2014; 6:325. DOI:10.3389/fnagi.2014.00325 · 2.84 Impact Factor
  • Source
    • "Longitudinal and neuropathological studies indicate that Alzheimer's disease (AD) has a long protracted preclinical phase, where the pathological changes are occurring 10–15 years prior to the emergence of clinical symptoms (Pike et al., 2011; Price et al., 2009). As a result, clinical trials for AD have moved toward preventing decline in clinically normal (CN) older adults who have biomarker evidence of AD but still perform "
    [Show abstract] [Hide abstract]
    ABSTRACT: Neuropsychologists are developing more challenging and specific tests to detect early and subtle changes in cognition related to preclinical Alzheimer's disease (AD). The 16-item Face-Name Associative Memory Exam (FNAME-16) is a challenging paired associative memory test able to detect subtle memory changes associated with biomarker evidence of preclinical AD. However, as individuals progress along the AD trajectory, measures that are sensitive at the preclinical stage may become too challenging by the stage of Mild Cognitive Impairment (MCI). Our goal was to develop a modified version of the face-name and face-occupation paired associative memory task (FNAME-12) with fewer stimuli and additional learning trials suitable for use in MCI. We administered the FNAME-12A, an alternate version FNAME 12B, the original FNAME-16, and a series of other neuropsychological measures to 65 clinically normal (CN) older adults (aged 65 to 85) and a subsample characterized by MCI (n = 18). The FNAME-12 exhibited psychometric equivalence with the FNAME-16 (r = .77, p < .001) and was correlated with other measures of episodic and semantic memory. The alternate form, FNAME-12B, was highly correlated with FNAME-12A (r = .76, p < .001). Mean performance on the FNAME 12A, stratified by education, was generated. The task could be completed by our MCI group yet remained challenging in the CN group, providing evidence for its utility along the AD trajectory.
    The Clinical Neuropsychologist 05/2014; 28(5):1-15. DOI:10.1080/13854046.2014.911351 · 1.58 Impact Factor
Show more